Non-small cell lung cancer KRAS mutations are present in approximately one-fourth of human tumors and are one of the clearest targets in the field of oncology drug discovery. Unfortunately, despite its promise, KRAS has long been virtually impossible to overcome, due to the fact that the protein is a featureless, nearly spherical structure with no obvious binding site, making it difficult to synthesize a compound that can target and inhibit its activity. This has made KRAS synonymous with “non-druggable” targets in the field of oncology drug discovery and development. It was not until Sotorasib came out of nowhere that 36% of patients with KRASG12C mutated NSCLC had their tumors shrunk by more than 30%, breaking the history of KRAS as a non-druggable target. Currently, many domestic companies are conducting related clinical trials with similar products. Recently, our hospital is also conducting a clinical trial for lung cancer combined with KRASG12C mutation, which can enroll patients who have failed chemotherapy in the past. The following figure is one of the patients who have participated in the study at the end of last year, who has received second-line chemotherapy and progressed, and the comparison of CT images after and before treatment with KRASG12C oral targeted drugs shows that the efficacy of this kind of drugs is still good. .